Bosutinib Correct Dosing Guide and Precautions

Bosutinib (Bosutinib) is an oral tyrosine kinase inhibitor (TKI), mainly used to treat chronic myelogenous leukemia (CMLCML pan>), especially suitable for patients who are resistant or intolerant to first-generation TKIs such as imatinib (Imatinib). As a targeted drug targeting the BCR-ABL fusion gene, bosutinib is of great value in improving the treatment rate of CML and prolonging the progression-free survival of patients. In order to fully exert the efficacy of the drug and reduce side effects, patients need to understand the correct method of taking bosutinib and related precautions.

1. Recommended dosage and medication method

The recommended dose of bosutinib is usually 400mg or 500mg once daily. The specific dose is determined based on factors such as disease stage, patient weight, and tolerance. For patients newly diagnosed with CML in the chronic phase, the recommended initial dose is 400 mg; for patients who have previously received other TKI treatments but developed resistance or intolerance, the initial dose may be adjusted to 500 mg per day.

Bosutinib must be taken with food and is not recommended on an empty stomach. When taking the medicine, swallow the tablet whole. Do not chew, break or crush the tablet, otherwise it may affect the drug release rate and absorption effect. It is recommended to take the medicine at a fixed time every day to maintain a stable drug concentration in the body, thereby improving the therapeutic effect and reducing fluctuating side effects.

2. Precautions during taking medication

Patients should pay special attention to the following points during treatment with bosutinib:

Dietary Coordination: Bosutinib should be taken with a meal to increase absorption and reduce the risk of gastrointestinal discomfort. If taken on an empty stomach, it may aggravate gastrointestinal side effects such as nausea and diarrhea. In addition, eating grapefruit or drinking grapefruit juice should be avoided because it may inhibit the activity of CYP3A4 enzyme, thereby increasing the plasma concentration of bosutinib and increasing the risk of toxicity.

Avoid missing doses: If you miss a dose for some reason, you should take it as soon as possible on the same day. However, if it is close to the time of the next dose, you should skip the missed dose and do not double the dose. Taking your medication regularly is crucial to maintaining its effectiveness.

Hydration and gastrointestinal reaction management: The more common side effects of bosutinib are diarrhea, nausea, and vomiting. It is recommended that patients ensure adequate fluid intake while taking the medication, and may use antidiarrheal drugs (such as loperamide) as appropriate according to the doctor's advice. If diarrhea persists or worsens, seek medical attention promptly.

3. Interactions with other drugs

Bosutinib is mainly metabolized by the CYP3A4 enzyme in the liver, so you need to be wary of interactions with other drugs during use. The following are several types of drugs that require special attention:

StrongCYP3A4Inhibitors (such as ketoconazole, clarithromycin): may cause an increase in the blood concentration of bosutinib, so combination use should be avoided, or the dose should be adjusted under the guidance of a doctor.

CYP3A4Inducers (such as rifampicin, carbamazepine): may reduce the concentration of bosutinib and weaken the efficacy, and should also be avoided as much as possible.

Antacid drugs (such as proton pump inhibitors): may reduce the absorption of bosutinib, and it is recommended to stagger the taking time. If you need to use antacids, you can choose H2 receptor antagonists and wait at least 2 hours after taking bosutinib before taking antacids.

4. Monitoring and side effects response during treatment

During bosutinib treatment, the following indicators need to be monitored regularly to ensure medication safety:

Liver function monitoring: Bosutinib may cause an increase in transaminases. It is recommended to check liver function every 2 to 4 weeks, especially in the early stages of treatment.

Routine blood tests: such as white blood cells, platelets, red blood cells, etc., to determine the risk of bone marrow suppression, especially when symptoms such as fatigue, bleeding, infection, etc. occur, check immediately.

Renal function, electrolytes, and electrocardiogram: Patients taking bosutinib for a long time should regularly check renal function, potassium and sodium ion levels, and electrocardiogram to prevent potential risks.

Common adverse reactions, such as mild to moderate diarrhea, can be controlled by adjusting diet and rehydration, and using symptomatic drugs if necessary. Symptoms such as rashes, headaches, and muscle aches are mostly temporary. If they persist or are severe, you should communicate with your doctor in time and consider reducing the dosage or changing the treatment plan.

5. Medication recommendations for special groups of people

Bosutinib should be used with caution in the elderly, patients with impaired hepatic function, or patients with other underlying medical conditions. Some people may metabolize drugs slowly, increasing the risk of adverse reactions. Therefore, doctors may use a lower starting dose and closely monitor response based on the patient's specific circumstances.

Bosutinib is not recommended for women who are pregnant or breastfeeding because of the potential risk to the fetus or baby. Women of childbearing age should take effective contraceptive measures while taking the drug, and fully communicate with their doctor before planning pregnancy to consider the risks and benefits of taking the drug.

Bosutinib is an important targeted drug for the treatment of chronic myelogenous leukemia. Correct medication administration and strict medication management are crucial to ensure efficacy and safety. During the course of taking it, patients should pay attention to taking the medicine at regular times every day with meals, avoid drug interactions, actively respond to adverse reactions, and undergo relevant medical examinations regularly. At the same time, do not stop the medication or increase or decrease the dose without authorization, and make sure to use the medication under the guidance of a doctor. Through scientific and standardized medication, patients are expected to achieve better disease control and improved quality of life.

Reference materials:https://www.drugs.com/